Nanomix Corporation (OTC-PINK: NNMXD, NNMX) will participate in the 2022 Virtual Growth Conference hosted by Maxim Group LLC from March 28-30, 2022. CEO David Ludvigson will present a company overview during the event. A pre-recorded presentation will be accessible for 72 hours from March 28, 9:00 a.m. ET, and an archived replay will be available on Nanomix's investor relations website.
Nanomix Corporation (OTC-PINK:NNMX) has successfully completed a reverse stock split of its common stock at a ratio of 1-for-173, reducing outstanding shares from approximately 917 million to about 5.3 million. This split, announced on June 29, 2021, will improve stock visibility among investors and supports the Company's growth strategy. Trading under a temporary symbol 'NNMXD' will commence on March 2, 2022, reverting to 'NNMX' after 20 business days. The reverse stock split also adjusts outstanding preferred shares, stock options, and warrants accordingly.
Nanomix Corporation (OTC: NNMX) announced MHRA registration of its eLab system and S1 Panel Cartridge in the UK, enhancing market introduction of its diagnostics solutions. The eLab analyzer allows rapid, bedside diagnostics for critical infections, including sepsis, by providing multiple results from a single sample in under 11 minutes. The S1 Panel measures biomarkers like C-reactive protein and Procalcitonin to assist in treatment decisions. This registration follows the CE mark acquisition, marking significant progress for Nanomix in improving healthcare delivery.
Nanomix Corporation (OTC: NNMX) has resubmitted its Emergency Use Authorization (EUA) application to the U.S. FDA for the eLab COVID-19 rapid antigen test. This application includes enhanced analytical and clinical data following FDA feedback. The eLab test, designed for quick results in 15 minutes, utilizes nasal swab samples. CEO David Ludvigson expressed optimism about FDA review and the potential for the test to improve COVID-19 testing accessibility.
Nanomix Corporation, formerly known as Nanomix, Inc., has changed its name and ticker symbol from BTHE to NNMX following a reverse merger with Boston Therapeutics, Inc.. The new ticker symbol NNMX is now active on the OTC Market. Nanomix specializes in developing mobile point-of-care diagnostics aimed at improving healthcare delivery with rapid, accurate testing for critical infections and COVID-19. The company continues to expand its pipeline to enhance diagnostic capabilities.